智通财经APP获悉,周三,乌龙制药(UroGen Pharma,URGN.US)股价暴跌约47%,此前美国食品药品监督管理局(FDA)顾问委员会对该公司的膀胱癌疗法UGN-102(丝裂霉素)投下反对票,这款药物目前正在美国接受监管审查。在针对膀胱内注射溶液的风险获益比问题上,FDA肿瘤药物顾问委员会(ODAC)以4票赞成、5票反对的结果否决了该药物。这对正寻求UGN-102美国批准的乌龙制药来说是...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.